{
    "SPADE_N_06005": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_06005",
            "Peptide Name": "Mastoparan-C(MP-C)",
            "Source": "Vespa crabro",
            "Family": "Not found",
            "Gene": "N/A",
            "Sequence": "LNLKALLAVAKKIL",
            "Sequence Length": 14,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P01516"
            ],
            "Protein Existence": "Protein level",
            "Biological Activity": [
                "Antimicrobial",
                "Antibacterial",
                "Anti-Gram+",
                "Anti-Gram-",
                "Anticancer",
                "Antifungal"
            ],
            "Target Organism": "[Ref.29904274]Gram-positive bacteria:Staphylococcus aureus NCTC 10788(MIC=2 µM); Staphylococcus aureus NCTC 10788(MBC=2 µM); Staphylococcus aureus ATCC 12493(MRSA,MIC=4 µM); Staphylococcus aureus ATCC 12493(MRSA,MBC=4 µM); Enterococcus faecalis NCTC 12697(MIC=8 µM); Enterococcus faecalis NCTC 12697(MBC=8 µM);Gram-negative bacteria:Escherichia coli NCTC 10418(MIC=4 µM); Escherichia coli NCTC 10418(MBC=8 µM); Pseudomonas aeruginosa ATCC 27853(MIC=8 µM); Pseudomonas aeruginosa ATCC 27853(MBC=16 µM);    Fungi:Candida albicans NCTC 1467(MIC=4 µM); Candida albicans NCTC 1467(MBC=4 µM);Cancer:Human squamous lung carcinoma NCI-H157(IC50=13.57 µM);Human breast adenocarcinoma MDA-MB-435S(IC50=27.70 µM);Human prostate adenocarcinoma PC-3(IC50=6.29 µM);Human glioblastoma U251-MG(IC50=36.65 µM); Human breast adenocarcinoma MCF-7(IC50=25.27 µM).[Ref.33285267]Gram-positive bacteria:Staphylococcus aureus ATCC 25923(MIC=4 µM); Bacillus subtilis ATCC 23857(MIC=4 µM);Gram-negative bacterial:Escherichia coli ATCC 25922(4.5 mM KCl and 0.004 mM FeCl3,MIC=4 µM); Pseudomonas aeruginosa ATCC 9027(4.5 mM KCl,MIC=8 µM); Klebsiella pneumoniae ATCC 700603(MIC=8 µM); Escherichia coli ATCC 25922(NaCl/MgCl2=150mM/1mM,MIC=4 µM); Pseudomonas aeruginosa ATCC 9027(NaCl/MgCl2=150mM/1mM,MIC=16 µM); Pseudomonas aeruginosa ATCC 9027(0.004mM FeCl3,MIC=4 µM);Escherichia coli(Rifampin-resistant strain,MIC=4 µM).",
            "Hemolytic Activity": "[Ref.29904274]50% hemolysis against horse erythrocytes at 40.11 µM.[Ref.33285267]10% hemolysis against mouse erythrocytes at 64 µM; 60% hemolysis against mouse erythrocytes at 256 µM.",
            "Cytotoxicity": "[Ref.29904274]Cytotoxicity:Human microvascular endothelial cells HMEC-1(IC50=57.15 µM).[Ref.33285267]90% Killing against Human embryonic kidney HEK293T cells at 128 µM; Human embryonic kidney HEK293T cells(IC50=16 µM).",
            "Binding Target": "liposomes",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Free",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "The CD spectra in water adopts a random-coil conformation,24.85% α-helix was determined in 50% TFE.",
            "Formula": "C72H134N18O16",
            "Mass": 1507.95,
            "PI": 10.3,
            "Net Charge": 3,
            "Hydrophobicity": 1.28,
            "Half Life": "Mammalian:5.5 hourYeast:3 minE.coli:2 min",
            "Function": "The peptide was tolerant in the presence of physiological salts.MP-C  lost antimicrobial activities after incubation with 20 μg/mL trypsin or chymotrypsin,indicating moderate protease resistance.",
            "Literature": [
                {
                    "Title": "Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria.",
                    "Pubmed ID": "33285267",
                    "Reference": "Eur J Pharm Sci. 2021 Mar 1;158105665.",
                    "Author": "Zhu N, Zhong C, Liu T, Zhu Y, Gou S, Bao H, Yao J, Ni J.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=33285267"
                },
                {
                    "Title": "Evaluation of the bioactivity of a mastoparan peptide from wasp venom and of its analogues designed through targeted engineering.",
                    "Pubmed ID": "29904274",
                    "Reference": "Int J Biol Sci. 2018 Apr 25;14(6)599-607.",
                    "Author": "Chen X, Zhang L, Wu Y, Wang L, Ma C, Xi X, Bininda-Emonds ORP, Shaw C, Chen T, Zhou M.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=29904274"
                },
                {
                    "Title": "Isolation and characterization of two new peptides, mastoparan C and crabrolin, from the venom of the European hornet, Vespa crabro.",
                    "Pubmed ID": "",
                    "Author": "Pisano J.J.,Argiolas A."
                }
            ],
            "Frequent Amino Acids": "LAK",
            "Absent Amino Acids": "CDEFGHMOPQRSTUWY",
            "Basic Residues": 3,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 10,
            "Polar Residues": 8,
            "Positive Residues": 3,
            "Negative Residues": 0,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_13465",
                    "Similarity": 1.0,
                    "Sequence": "CLNLKALLAVAKKILC"
                },
                {
                    "SPADE_ID": "SPADE_UN_13466",
                    "Similarity": 1.0,
                    "Sequence": "RKKRRQRRRLNLKALLAVAKKIL"
                },
                {
                    "SPADE_ID": "SPADE_UN_13485",
                    "Similarity": 1.0,
                    "Sequence": "LNLKALLAVAKKI"
                }
            ]
        }
    }
}